[Evaluation of the effectiveness and tolerability of MED 15 vs. piroxicam in patients with acute epicondylitis]. / Valutazione dell'efficacia e tollerabilità di MED 15 verso piroxicam in pazienti affetti da epicondilite acuta.

In this trial we studied 30 patients with acute epicondylitis: 15 were treated with Med 15, a new non-steroidal anti-inflammatory drug, and 15 with piroxicam. Med 15 was administered orally for 15 days: the first 2 days 2 tablets daily (1.200 mg) and the following 13 days 1 tablet daily (600 mg). Piroxicam was administered 2 tablets the first 2 days and 1 tablet daily the following 13 days. It was demonstrated that the new compound is significantly more active and better tolerated than the reference drug.